CIDARA THERAPEUTICS, INC.

(CDTX)
  Report
Delayed Nasdaq  -  05/20 04:00:01 pm EDT
0.4444 USD   -6.42%
05/12HC Wainwright Adjusts Cidara Therapeutics Price Target to $6 From $7.50, Maintains Buy Rating
MT
05/11CIDARA THERAPEUTICS : Q1 Earnings Snapshot
AQ
05/11Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q1 Revenue $7.1M
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/16/2022 05/17/2022 05/18/2022 05/19/2022 05/20/2022 Date
0.4465(c) 0.4829(c) 0.4621(c) 0.4749(c) 0.4444(c) Last
640 076 520 294 180 342 105 930 225 270 Volume
+4.32% +8.15% -4.31% +2.77% -6.42% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 25,0 M - -
Net income 2022 -76,1 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,40x
Yield 2022 -
Sales 2023 31,5 M - -
Net income 2023 -73,2 M - -
Net Debt 2023 - - -
P/E ratio 2023 -0,48x
Yield 2023 -
Capitalization 30,7 M 30,7 M -
Capi. / Sales 2022 1,23x
Capi. / Sales 2023 0,98x
Nbr of Employees 89
Free-Float 88,2%
More Financials
Company
Cidara Therapeutics, Inc. is a biotechnology company. The Company is focused on the discovery, development and commercialization of therapeutics designed for the care of patients facing serious fungal or viral infections. The Company's lead product candidate is rezafungin acetate, an intravenous formulation of a echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and... 
Sector
Biotechnology & Medical Research
Calendar
06/22 | 11:00amShareholder meeting
More about the company
Ratings of Cidara Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about CIDARA THERAPEUTICS, INC.
05/12HC Wainwright Adjusts Cidara Therapeutics Price Target to $6 From $7.50, Maintains Buy ..
MT
05/11CIDARA THERAPEUTICS : Q1 Earnings Snapshot
AQ
05/11Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q1 Revenue $7.1M
MT
05/11Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial ..
GL
05/11Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial ..
GL
05/11CIDARA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
AQ
05/11Cidara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31..
CI
04/26Mundipharma and cidara therapeutics announce first presentation of results from global ..
AQ
04/26Mundipharma and cidara therapeutics announce first presentation of results from global ..
AQ
04/25Mundipharma and Cidara Therapeutics Announce First Presentation of Results from Global ..
BU
04/25Mundipharma and Cidara Therapeutics Announces First Presentation of Results from Global..
CI
04/14Cidara Therapeutics and Mundipharma to Present Results from Global Phase 3 ReSTORE Tria..
AQ
04/04CIDARA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
04/04Cidara Therapeutics, Inc. Announces Executive Changes
CI
03/31Cidara Therapeutics Says First Cohort Dosed in Phase 1 Trial of Influenza Treatment; Sh..
MT
More news
News in other languages on CIDARA THERAPEUTICS, INC.
05/11Earnings Flash (CDTX) CIDARA THERAPEUTICS affiche un chiffre d'affaires de 7,1 millions..
05/11Cidara Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 ma..
04/26Mundipharma und Cidara Therapeutics kündigen erste Präsentation der Ergebnisse aus der ..
04/25Mundipharma et Cidara Therapeutics annoncent la première présentation des résultats de ..
04/04Cidara Therapeutics, Inc. annonce des changements de direction
More news
Analyst Recommendations on CIDARA THERAPEUTICS, INC.
More recommendations
Chart CIDARA THERAPEUTICS, INC.
Duration : Period :
Cidara Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CIDARA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 0,44 $
Average target price 5,67 $
Spread / Average Target 1 175%
EPS Revisions
Managers and Directors
Jeffrey L. Stein President, Chief Executive Officer & Director
Preetam Shah Chief Financial, Accounting & Business Officer
Taylor Sandison Chief Medical Officer
Les Tari Chief Scientific Officer
Paul Daruwala Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
CIDARA THERAPEUTICS, INC.-65.01%31
GILEAD SCIENCES, INC.-12.08%80 075
REGENERON PHARMACEUTICALS, INC.4.69%71 235
VERTEX PHARMACEUTICALS17.76%66 136
WUXI APPTEC CO., LTD.-16.92%42 735
BIONTECH SE-36.77%39 612